Omega Therapeutics (Omega Therapeutics) EV-to-EBIT : -1.85 (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Omega Therapeutics's Enterprise Value is $175.69 Mil. Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-94.89 Mil. Therefore, Omega Therapeutics's EV-to-EBIT for today is -1.85.

The historical rank and industry rank for Omega Therapeutics's EV-to-EBIT or its related term are showing as below:

OMGA' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.29 Med: -1.92 Max: 0.94
Current: -1.85

During the past 5 years, the highest EV-to-EBIT of Omega Therapeutics was 0.94. The lowest was -6.29. And the median was -1.92.

OMGA's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs OMGA: -1.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Omega Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $268.90 Mil. Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-94.89 Mil. Omega Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -35.29%.

Omega Therapeutics EV-to-EBIT Historical Data

The historical data trend for Omega Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics EV-to-EBIT Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-5.09

-1.68

-2.20

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial													-2.00	-2.77	-1.45	-2.20	-2.83

Competitive Comparison of Omega Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Omega Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's EV-to-EBIT falls into.

Omega Therapeutics EV-to-EBIT Calculation

Omega Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	175.686	/	-94.893
	=	-1.85

Omega Therapeutics's current Enterprise Value is $175.69 Mil.
Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.89 Mil.

Omega Therapeutics (NAS:OMGA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Omega Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-94.893	/	268.89775
	=	-35.29 %

Omega Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $268.90 Mil.
Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.89 Mil.

Omega Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Omega Therapeutics (Omega Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.

Executives

Michelle C Werner	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade	director	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young	director, 10 percent owner	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus	officer: Chief Human Resources Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng	officer: See Remarks	C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore	officer: Chief Medical Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney	officer: Chief Financial Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142